Lonigutamab Phase 1/2 Proof-of-concept Data in Thyroid Eye Disease Mar 20, 2024 8:30 AM EDT Click here for webcast Supporting Materials Lonigutamab Phase 1/2 Proof-of-concept Data in Thyroid Eye Disease Presentation 1.8 MB Lonigutamab Phase 1/2 Proof-of-concept Data in Thyroid Eye Disease Press Release 252.7 KB